| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
119,920,000 |
| Market
Cap: |
2.20(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$14.96 - $32.96 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Denali Therapeutics is a biopharmaceutical company that discovers and develops therapeutics to defeat neurodegenerative diseases. Co.'s clinical-stage programs are: leucine-rich repeat kinase 2 inhibitor program to address Parkinson's disease; enzyme transport vehicle :IDS program, its lead brain-penetrant enzyme replacement therapy, enabled by its enzyme transport vehicle, which is designed to restore iduronate 2-sulfatase, and reduce glycosaminoglycans, both peripherally and in the brain, in patients with mucopolysaccharidosis II; and eukaryotic initiation factor 2 B activator program to address diseases such as amyotrophic lateral sclerosis and frontotemporal dementia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
136,870 |
194,989 |
260,525 |
524,601 |
| Total Sell Value |
$2,679,704 |
$3,814,194 |
$5,546,549 |
$13,449,119 |
| Total People Sold |
5 |
5 |
5 |
6 |
| Total Sell Transactions |
10 |
19 |
38 |
75 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Schuth Alexander O. |
COFO and Secretary |
• – – |
2023-02-08 |
4 |
S |
$30.89 |
$46,984 |
I/I |
(1,521) |
499,902 |
|
-4% |
|
| Krognes Steve E. |
Director |
– • – |
2023-02-08 |
4 |
S |
$30.88 |
$42,522 |
D/D |
(1,377) |
145,121 |
|
-4% |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2023-02-08 |
4 |
S |
$30.88 |
$46,968 |
I/I |
(1,521) |
180,183 |
|
-4% |
|
| Schuth Alexander O. |
COFO and Secretary |
• – – |
2023-01-17 |
4 |
AS |
$29.53 |
$295,339 |
I/I |
(10,000) |
497,173 |
|
-1% |
|
| Schuth Alexander O. |
COFO and Secretary |
• – – |
2023-01-17 |
4 |
OE |
$5.28 |
$52,800 |
I/I |
10,000 |
507,173 |
|
- |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2023-01-09 |
4 |
AS |
$28.48 |
$41,552 |
I/I |
(1,459) |
177,454 |
|
9% |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2023-01-06 |
4 |
AS |
$28.67 |
$41,600 |
I/I |
(1,451) |
178,913 |
|
3% |
|
| Watts Ryan J. |
President and CEO |
• • – |
2023-01-05 |
4 |
S |
$28.44 |
$136,512 |
I/I |
(4,800) |
2,223,664 |
|
-2% |
|
| Krognes Steve E. |
Director |
– • – |
2023-01-05 |
4 |
S |
$28.44 |
$84,467 |
D/D |
(2,970) |
146,498 |
|
-2% |
|
| Schuth Alexander O. |
COFO and Secretary |
• – – |
2023-01-05 |
4 |
S |
$28.44 |
$74,968 |
I/I |
(2,636) |
497,173 |
|
-2% |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2023-01-05 |
4 |
AS |
$28.44 |
$74,968 |
I/I |
(2,636) |
180,364 |
|
2% |
|
| Schuth Alexander O. |
COFO and Secretary |
• – – |
2023-01-04 |
4/A |
S |
$28.70 |
$83,574 |
I/I |
(2,912) |
492,309 |
|
- |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2023-01-04 |
4 |
S |
$28.69 |
$83,574 |
I/I |
(2,913) |
175,500 |
|
-11% |
|
| Watts Ryan J. |
President and CEO |
• • – |
2023-01-04 |
4 |
S |
$28.73 |
$144,483 |
I/I |
(5,029) |
2,213,464 |
|
-11% |
|
| Schuth Alexander O. |
COFO and Secretary |
• – – |
2023-01-04 |
4 |
S |
$28.70 |
$83,574 |
D/D |
(2,912) |
149,828 |
|
-11% |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
41,120 |
138,967 |
|
- |
|
| Watts Ryan J. |
President and CEO |
• • – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
82,240 |
231,934 |
|
- |
|
| Schuth Alexander O. |
COFO and Secretary |
• – – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
41,120 |
157,578 |
|
- |
|
| Tessier-Lavigne Marc |
Director |
– • – |
2022-11-23 |
4 |
AS |
$30.48 |
$609,600 |
D/D |
(20,000) |
1,870,356 |
|
-21% |
|
| Tessier-Lavigne Marc |
Director |
– • – |
2022-11-02 |
4 |
AS |
$30.33 |
$341,273 |
D/D |
(11,252) |
1,890,356 |
|
-24% |
|
| Tessier-Lavigne Marc |
Director |
– • – |
2022-11-01 |
4 |
AS |
$30.20 |
$264,190 |
D/D |
(8,748) |
1,901,608 |
|
-18% |
|
| Schuth Alexander O. |
COFO and Secretary |
• – – |
2022-10-07 |
4 |
OE |
$0.68 |
$13,600 |
I/I |
20,000 |
487,471 |
|
- |
|
| Tessier-Lavigne Marc |
Director |
– • – |
2022-09-28 |
4 |
AS |
$30.74 |
$616,304 |
D/D |
(20,000) |
1,910,356 |
|
-7% |
|
| Tessier-Lavigne Marc |
Director |
– • – |
2022-08-23 |
4 |
AS |
$31.61 |
$632,282 |
D/D |
(20,000) |
1,930,356 |
|
-10% |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2022-08-23 |
4 |
AS |
$31.98 |
$77,520 |
I/I |
(2,424) |
170,663 |
|
-10% |
|
416 Records found
|
|
Page 4 of 17 |
|
|
0.36 (1.93%) 
